Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.

Area of Science:

• Biochemistry
• Hepatology
• Virology

Background:

• Hepatitis C virus (HCV) infection disrupts lysophosphatidylcholine (LPC) metabolism, impacting viral infectivity.
• Direct-acting antivirals (DAAs) are effective HCV treatments that normalize serum cholesterol.
• LPC species in serum are associated with albumin and lipoproteins.

Purpose of the Study:

• To investigate the effect of HCV eradication on serum LPC species levels.
• To compare LPC profiles before and after DAA therapy in HCV patients.
• To evaluate the association of LPC levels with liver cirrhosis and disease severity.

Main Methods:

• Measurement of 12 LPC species using electrospray ionization tandem mass spectrometry (ESI-MS/MS).
• Analysis of serum samples from 178 chronic HCV patients at baseline and 176 post-DAA therapy.
• Correlation analysis with Model for End-Stage Liver Disease (MELD) score and albumin levels.

Main Results:

• All measured LPC species significantly increased after DAA therapy.
• Serum LPC profiles remained similar before and after viral cure.
• HCV patients with liver cirrhosis showed lower overall LPC levels (except LPC 16:1) and altered LPC 18:1, 22:5, and 22:6 percentages.
• LPC levels correlated inversely with MELD score and directly with albumin.
• Elevated % LPC 18:1 showed potential for classifying liver fibrosis (AUC 0.773 at baseline, 0.720 post-therapy).

Conclusions:

• HCV elimination by DAAs leads to a comprehensive increase in serum LPC species.
• Specific LPC species alterations, particularly elevated LPC 18:1, may indicate pathological roles in HCV-related liver cirrhosis.
• LPC profiling could serve as a biomarker for liver fibrosis severity in HCV patients.